Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects
Alexandra AI Abel, Andrew L Clark Department of Academic Cardiology, Castle Hill Hospital, Kingston Upon Hull, UKCorrespondence: Alexandra AI AbelDepartment of Academic Cardiology, Castle Hill Hospital, Cottingham, Kingston-Upon-Hull, HU16 5JQ, UKEmail alexandra.abel@hyms.ac.ukAbstract: Heart failur...
Guardado en:
Autores principales: | Abel AAI, Clark AL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9d2212fca2bb49598182515b0b72ab76 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure
por: Pema Raj, et al.
Publicado: (2021) -
The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study
por: Alexey A. Nekrasov, et al.
Publicado: (2019) -
Admission Glucose Levels and Associated Risk for Heart Failure After Myocardial Infarction in Patients Without Diabetes
por: Viveca Ritsinger, et al.
Publicado: (2021) -
Innate Lymphoid Cells and Myocardial Infarction
por: Wenling Yang, et al.
Publicado: (2021) -
Protective role of emodin in rats with post-myocardial infarction heart failure and influence on extracellular signal-regulated kinase pathway
por: Jinfeng Liu, et al.
Publicado: (2021)